EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances of the small molecule drugs regulating fibroblast-like synovial proliferation for rheumatoid arthritis

Yitong Tong, Xinyu Li, Qichuan Deng, Jianyou Shi, Yibin Feng, Lan Bai

Frontiers in Pharmacology · 21.07.2023 · 14

DOI: 10.3389/fphar.2023.1230293 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.07.2023. Verfasst von Yitong Tong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu Second People's Hospital, Chengdu, Sichuan, China. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Sichuan Province Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is a type of chronic autoimmune and inflammatory disease. In the pathological process of RA, the alteration of fibroblast-like synoviocyte (FLS) and its related factors is the main influence in the clinic and fundamental research. In RA, FLS exhibits a uniquely aggressive phenotype, leading to synovial hyperplasia, destruction of the cartilage and bone, and a pro-inflammatory environment in the synovial tissue for perpetuation and progression. Evidently, it is a highly promising way to target the pathological function of FLS for new anti-RA drugs. Based on this, we summed up the pathological mechanism of RA-FLS and reviewed the recent progress of small molecule drugs, including the synthetic small molecule compounds and natural products targeting RA-FLS. In the end, there were some views for further action. Compared with MAPK and NF-κB signaling pathways, the JAK/STAT signaling pathway has great potential for research as targets. A small number of synthetic small molecule compounds have entered the clinic to treat RA and are often used in combination with other drugs. Meanwhile, most natural products are currently in the experimental stage, not the clinical trial stage, such as triptolide. There is an urgent need to unremittingly develop new agents for RA.

Schlagwörter

Stichwörter der Autor:innen

fibroblast-like synoviocytesnatural productsrheumatoid arthritissignaling pathwayssmall molecule drugs

Autor:innen und Institutionen

  • Chengdu Second People's Hospital, Chengdu, Sichuan, China.
  • Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science an…
  • School of Chinese Medicine, The University of Hong Kong, Shatin, Hong Kong SAR, China.

Förderung

  • National Natural Science Foundation of China
  • Sichuan Province Science and Technology Support Program

Zitieren

APA

Tong, Y., Li, X., Deng, Q., Shi, J., Feng, Y., & Bai, L. (2023). Advances of the small molecule drugs regulating fibroblast-like synovial proliferation for rheumatoid arthritis. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1230293

Vancouver

Tong Y, Li X, Deng Q, Shi J, Feng Y, Bai L. Advances of the small molecule drugs regulating fibroblast-like synovial proliferation for rheumatoid arthritis. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1230293

BibTeX
@article{Tong2023,
  author = {Tong, Yitong and Li, Xinyu and Deng, Qichuan and Shi, Jianyou and Feng, Yibin and Bai, Lan},
  title = {Advances of the small molecule drugs regulating fibroblast-like synovial proliferation for rheumatoid arthritis},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1230293}
}
Kostenlos starten →